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Abstract
Background:  We present evidence that a major aspect of the mechanism of acute signal
transduction regulation by insulin-like growth factor-1 (IGF-1) in cultured murine myoblasts is
associated with a broad perturbation of many components of cholesterol and fatty acid biosynthetic
pathways.
Results: We have used microarray transcriptional analysis to examine the acute effects of IGF-1
on global patterns of gene expression in C2C12 myoblasts and have identified approximately 157
genes that are up-regulated and 75 genes down-regulated from 2- to 6-fold after treatment with
IGF-1. Of the up-regulated genes, 19 genes are associated with cholesterol biosynthesis and 5 genes
specify aspects of fatty acid biosynthesis. In addition 10 recognized transcription factors are
significantly induced by IGF-1 at 1 hour.
Conclusion: The SREBPs, important regulators of fatty acid and cholesterol biosynthesis, operate
via a post-transcriptional route and no significant transcriptional induction was observed in the 4
hr of IGF-1 treatment. Since there are no prior reports of significant and coordinated perturbations
of fatty acid and cholesterol biosynthetic pathways with IGF-1 in muscle cells, these findings provide
a substantive expansion of our understanding of IGF-1 action and the signal transduction pathways
mediated by it, its variants and insulin.
Background
IGF-1 is a multifunctional polypeptide hormone that
plays a central role in controlling somatic growth and par-
ticipates in muscle development, maintenance and regen-
eration [1-3]. Several forms of IGF-1 exist as splicing
variants that are differentially distributed in different cell
types and may have associated cell type specific functions.
Whilst the main source of IGF-1 synthesis is the liver, its
target cells are mostly in the liver and muscle. Since mus-
cle constitutes over 40 percent of the body mass, it
becomes an important tissue to investigate the effects of
IGF-1. IGF-1 influences the development and mainte-
nance of muscle cells at least partly through the early acti-
vation of signal transduction pathway proteins leading to
the induction of specific transcription factors that conse-
quently trigger downstream target genes. Disruption of
IGF signaling by targeted knockout of the IGF-IR gene
causes growth impairment and severe skeletal muscle
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hypoplasia [4]. Conversely, over-expression of IGF-1 in
skeletal muscle stimulates hypertrophy and also counter-
acts loss of muscle mass that occurs during aging in mice
[2,5].
IGF-1, IGF-2 and insulin constitute a family of factors that
regulate normal development and cellular function fol-
lowing initial binding to their dimeric cell surface receptor
tyrosine kinases (IGF-1R, -2R and IR) [6]. IGF-1 and insu-
lin and their receptors (IR and IGF-1R) are structurally
closely related, but their actions result in markedly differ-
ent downstream changes in different cell and tissue types.
Although Insulin and IGF-1 cross-react with their non-
cognate receptors, each receptor binds its own ligand with
a 100- to 1000-fold higher affinity thus triggering a sign-
aling cascade that regulates cell differentiation, apoptosis
and, proliferation [7]. IGF-1 acting through its cognate
receptor does not stimulate lipogenesis or rescue the
lethal phenotype in mice that lacks the insulin receptor
(IR) [8]. The insulin (IR) and IGF-1 receptors (IGF-1R)
being structurally related, target several common intracel-
lular substrates. However, each hormone also elicits spe-
cific effects through differential phosphorylation of their
common substrates. For instance, differential phosphor-
ylation of FKHR, a forkhead transcription factor occurs in
response to signaling from insulin or IGF-1 receptor. In
IR-deficient hepatocytes, one (Thr24) of the three phos-
phorylation sites in FKHR was not phosphorylated,
though they express IGF-1R, resulting in distinctly differ-
ent outcomes [9]. In addition, IGF-1 action is regulated
via its interaction with multiple binding proteins [7,10].
A comparative microarray study investigating the effects
of IGF-1 and insulin (employing ~2222 probe sets) has
shown that 30 genes were specifically responsive to IGF-1
and 9 genes to insulin [11]. In mouse NIH-3T3 fibroblasts
IGF-1 induced mitogenesis and/or differentiation whereas
genes induced by insulin did not fall into any particular
category [12]. Exposure of C2 myoblasts to a mutated IGF-
1 derivative (for 24 hours) resulted in the differential reg-
ulation of about 90 genes [13]. Further the authors report
identifying 28 muscle-specific as well as 33 un-annotated
transcripts that are differentially expressed between IGF-1
and PDGF treatment of IGF-2-deficient murine C2 myob-
lasts.
In the present study we employed an Affymetrix mouse
array platform (comprising ~22, 600 probe sets) to inves-
tigate the acute affects of exogenously added IGF-1 on glo-
bal gene expression profiles in murine C2C12 myoblasts
by exposing these for 1, 2 and 4 hours. The proportion of
genes significantly affected by IGF-1 in this study is low
(<1% of the whole genome) and belong to a mixed array
of gene ontologies. Apart from the early induction or
repression of transcription factors with IGF-1 treatment, a
surprising finding was the coordinate induction of most
genes of two related pathways, namely the fatty acid and
cholesterol biosynthetic pathways. We therefore sought to
determine whether this coordinate up-regulation of fatty
acid and cholesterol biosynthetic genes in myoblasts, nor-
mally ascribed to as an insulin response, was modulated
by the hierarchical lipogenic sterol regulatory element
binding proteins (SREBPs). The SREBPs are not signifi-
cantly transcriptionally induced with IGF-1 treatment.
However, there is elegant evidence to suggest that these
transcriptional factors are regulated by a complex post-
transcriptional mechanism [14] and have been shown
more recently by Brown and collaborators [15] to operate
via Akt to induce ER-to-Golgi transport of the SREBP
cleavage-activating protein (SCAP) and thereby stimulate
SREBP processing.
Results
Global changes in gene expression
Murine C2C12 myoblast offers a robust model to study
the acute effects of IGF-1 as expression patterns obtained
here are indicative of the early changes leading to skeletal
myotubule differentiation. We therefore investigated
these global gene expression profiles following exposure
of myoblasts to IGF-1 for 1, 2 and 4 hours. Correlation of
data from the two independent experiments indicates
reproducible expression signals for each partner time
point at zero hour (data not shown). A similar correlation
was also obtained for the other experimental time points.
We tentatively selected a two-fold (or greater/lesser) crite-
ria (relative to control values) to be a conservative thresh-
old for measuring alterations in gene expression.
Pair-wise comparisons of microarray data, generated from
two independent experiments revealed that about twice
the number of genes are differentially up-regulated by
two-fold or greater levels as compared to genes whose
expression is down regulated (Fig. 1A) at the 1, 2 and 4
hours of IGF-1 treatment and the number of genes show-
ing increased expression increases through hour 4. The
proportion of genes significantly affected by IGF-1 (2-fold
or greater change) from the whole genome is low (<1%)
demonstrating the specificity of IGF-1 action on a subset
of genes. Though a number of the genes show some
change (ie >5%) with IGF-1 treatment, they are not
altered by the two-fold or greater criteria used here. On the
other hand, the expression of about 400 genes was wholly
unaffected (exhibiting < 5% change) with the treatment
and these signal levels were indistinguishable from con-
trol samples at all time points. These unaffected genes
belong to a mixed array of gene ontologies.
The temporal expression patterns of up- and down-regu-
lated genes is shown in Venn distributions (Figs 1B–C)
and the gene list for each overlapping and unique groupBMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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is tabulated (see Tables 1 and 2 and Additonal files 1 and
2). The expression of 12 genes is both persistently and
markedly up-regulated at all time points following IGF-1
treatment (Table 1). Genes such as Suppressor of cytokine
signaling 3 (Socs3), DNA-damage inducible transcript 4
(Ddit4), Cation transport regulator-like 1(Chac1) and
Hydroxysteroid (17 beta dehydrogenase 7 (Hsd17b7),
were induced at all time points (Table 1 and Additional
file 1). Only two genes, namely, Dual specificity phos-
phatase 1 (Dusp1) and Inhibitor of DNA binding 3 (Idb3),
were consistently down-regulated at all times (Table 2 and
Additional file 2).
Global changes in gene expression following exposure of murine myoblasts to IGF-1 Figure 1
Global changes in gene expression following exposure of murine myoblasts to IGF-1. The number of genes that are 
either up- or down-regulated following acute exposure of C2C12 myoblasts to IGF-1 is shown (Fig. 1A). More genes are up- 
than down-regulated by IGF-1 at all the time points studied. Several, early induced genes are transcription factors and few of 
these are consistently expressed at all times. More genes are induced or repressed at the later times indicating secondary 
affects on the expression of a larger number of target genes, following the early surge in transcription factor expression. Fig-
ures 1 B-C show the temporal pattern of up- and down-regulated genes following exposure of murine myoblasts to IGF-1. 
Data from Venn diagrams show that several early expressed genes are transcription factors. Only 12 and 2 genes are up- (Fig. 
1B) or down-(Fig. 1C) regulated, respectively, at all time points of acute IGF-1 treatment. At least 37 genes are induced at 2 hrs 
and remain so at 4 hrs. In contrast the expression of only 16 genes is repressed at 2 hrs and this remains so at 4 hrs. A tabu-
lated list of genes for each of these groups is given elsewhere (see Tables 1 and 2 and also Additional files 1 and 2). Genes con-
sidered here and in other sections represent a 2-fold or greater change with respect to the zero time point.
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Table 1: The temporal pattern of genes up-regulated with IGF-1 treatment
Affy. Id. Symbol Genes up-regulated at 1 hr only Fold Change
1452519_a_at Zfp36 Zinc finger protein 36 2.2
1450295_s_at Pvr Poliovirus receptor (pvr) 2.2
1427186_a_at Mef2a Myocyte enhancer factor 2A 2.2
1418102_at Hes1 Hairy and enhancer of split 1 2.2
1416442_at Ier2 Immediate early response 2 2.2
Genes up-regulated at 1 & 2 hrs
1427683_at Egr2 Early growth response 2 2.6
1427174_at Phlda3 Pleckstrin homology-like dom. family A, member 1 2.4
1419816_s_at Zfp36l2 Zinc finger protein 36, C3H type-like 2 2.4
1418835_at Phlda1 Pleckstrin homology-like dom. family A, member 1 2.4
1437626_at Zfp36l2 Zinc finger protein 36, C3H type-like 2 2.2
1436026_at Zfp703 zinc finger protein 703 2.2
Genes up-regulated at 1 & 4 hrs
1421077_at Sertad3 SERTA domain containing 3 2.5
Genes up-regulated at 1, 2 & 4 hrs
1455899_x_at Socs3 Suppressor of cytokine signalling 3 5.0
1451382_at Chac Cation transport regulator-like 1 5.0
1428306_at Ddit4 DNA-damage-inducible transcript 4 4.0
1417871_at Hsd17b7 Hydroxysteroid (17-beta) dehydrogenase 7 3.6
1424022_at Osgin1 Oxidative stress induced growth inhibitor 1 3.3
1418025_at Bhlhb2 Basic helix-loop-helix domain containing, class B2 3.3
1416029_at Klf10 Kruppel-like factor 10 3.2
1424709_at Sc5d Sterol-C5-desaturase 3.1
1456212_x_at Socs3 Suppressor of cytokine signaling 3 2.9
1448742_at Snai1 Snail homolog 1 2.9
1448170_at Siah2 Seven in absentia 2 2.7
1434204_x_at Shmt2 Serine hydroxymethyl transferase 2 (mito) 2.2
Genes up-regulated at 2 hrs only
1421228_at Ccl7 Chemokine (C-C motif) ligand 7 4.5
1422213_s_at Foxh1 Forkhead box H1 4.5
1449227_at Ch25h Cholesterol 25-hydroxylase 4.0
1438097_at Rab20 RAB20, member RAS oncogene family 3.3
1426706_s_at Xylb Xylulokinase homolog (H. influenzae) 3.3
1421215_a_at Slmap Sarcolemma associated protein 3.1
1428888_at Tmem33 Transmembrane protein 33 clone 3.1
1448125_at Rit2 Ras-like without CAAX 2 3.0
1452402_at Uchl3 Ubiquitin carboxyl-terminal esterase L3 3.0
1452412_at Hoxc8 Homeo box C8 2.9
1426958_at Rps9 Ribosomal protein S9 2.9
1425624_at Epm2aip1 EPM2A (laforin) interacting protein 1 2.8
1427583_at Rik RIKEN cDNA 4921505C17 gene 2.8
1441023_at Eif2s2 Eukaryotic translation initiation factor 2 beta 2.7
1426065_a_at Trib3 Tribbles homolog 3 (Drosophila) 2.6
425362_at Hrb1 HIV-1 Rev binding protein-like 2.6
1424950_at Sox9 SRY-box containing gene 9 2.6
1455904_at Gas5 Growth arrest specific 5 2.5
1456094_at Usp36 Ubiquitin specific peptidase 36 2.5
1449414_at Zfp53 Zinc finger protein 53 2.5
1453806_at Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 2.5
1417597_at Cd28 CD28 antigen 2.5
1422851_at Hmga2 High mobility group AT-hook 2 2.4
1450780_s_at Hmga2 High mobility group AT-hook 2 2.4
1445116_at Usp25 Ubiquitin-specific processing protease 2.4
1425500_x_at Coro2a Coronin, actin binding protein 2A 2.4
1449578_at Supt16h Suppressor of Ty 16 homolog 2.4
1449110_at Rhob Ras homolog gene family, member B 2.3
1425281_a_at Tsc22d3 TSC22 domain family 3 2.3
1437658_a_at Snord22 small nucleolar RNA, C/D box 22 2.3
1420961_a_at Ivns1abp Influenza virus NS1A binding protein 2.3BMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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The early induction events target a battery of transcription
factors which include, Early growth response 1 & 2 (Egr-1/
-2), Snail homolog 1(Snai1), Basic h-l-h domain contain-
ing class B2 (Bhlhb2), Zinc finger protein-36 (Zfp36), -97-
like (Zfp97l), -119 (Zfp119), Kruppel-like factor 10
(Klf10), and Immediate early response-2 (Ier2) genes, that
are all up-regulated following 1 hour of treatment. Of
these early responding transcription factors some, such as
the Early growth response-1 and -2 (Egr-1 and -2), Zn fin-
ger proteins-36 (Zfp36) and -119 (Zfp119), Immediate
early response (Ier2) and DNA-damage inducible tran-
script 4 (Ddit4) gene are transiently expressed (See Table
1) exhibiting reduced expression after the initial surge.
Other early-induced genes, for example snail homolog 1
(Snai1), Seven in absentia 2 (Siah2), Kruppel-like factor
10 (Klf10), Basic helix-loop-helix domain containing fac-
tor (Bhlhb2), remain so for the rest of the treatment.
Coordinate expression of fatty acid and cholesterol 
biosynthetic pathway genes
At 4 hours of treatment IGF-1 induced marked changes in
two major pathways; those for 5 genes of the fatty acid
and 19 genes of the cholesterol biosynthetic pathways.
The induced fatty acid genes include ATP citrate lyase
(Acly), Acetyl CoA synthase (Acs), Long chain Elongase
(Lce), Fatty acid synthase (Fas), Stearoyl-CoA desaturase 1
(Scd1)(Figs. 2A, B and Table 3). The key fatty acid regula-
tory gene, Acetyl CoA carboxylase alpha (Acc1) did not
respond to IGF-1 treatment, though its signal levels were
scored as 'Present' under Affymetrix' signal selection cate-
gories of 'Present (P), Absent (A), or Marginally (M)
present'.
The cholesterol biosynthetic pathway comprises multiple
enzymatic steps leading to cholesterol biosynthesis and
these genes are coordinately up-regulated by IGF-1 (Fig. 2
and Table 4). The key cholesterol biosynthetic enzymes,
namely HMG CoA reductase (Hmgcr) (~3.1-fold) (Fig.
2C) and 7 dehydrocholesterol reductase (7Dhcr) (~3.2-
fold) are up-regulated to similar extents. With the excep-
tion of the Hydroxysteroid dehydrogenase (Hsd-17b) (Fig.
2E), which is induced to over 6-fold levels, the other
inducible cholesterol pathway genes are stimulated to 3-
to 4-fold levels relative to untreated samples. In general,
initial changes in expression levels for most fatty acid and
cholesterol pathway genes is perceptible at 2 hours and is
more pronounced at 4 hours of treatment (Fig. 2 and
Table 4). The expression of sterol-C5 desaturase (Sc5d)
and Hsdh7 (Fig 2B and Fig 2E) genes, however, is signifi-
cantly induced at the earliest time point and remains
induced for the entire period of treatment.
Interestingly, the LDL receptor (Ldlr) (~2-fold), Star-
related Lipid transfer domain containing 4 (Startd4) (2.8-
fold) and cholesterol 25 hydroxylase (M25oh) (~4-fold)
genes that are involved in cholesterol uptake, transport,
and breakdown, respectively, are also up-regulated in the
same time frame (Fig 2F and Table 4).
Of the many transcriptional factors implicated in the reg-
ulation of fatty acid and cholesterol biosynthesis it was of
interest to examine the two principal factors SREBP-1 and
-2 (Fig. 3A, B). No measurable change was observed for
the SREBP-1 gene and no significant change (1.4-fold
increase) was observed for the SREBP-2 gene with IGF-1
treatment. The q-PCR data for SREBP-1 is at variance with
the microarray studies (Fig. 4J). SREBP-1 and -2 are not
significantly induced by IGF-1 treatment alone. However,
both SREBP-1 and -2 are significantly induced when IGF-
1 is treated in the presence of the cycloheximide (Fig. 3B),
1421512_at Cep250 Centrosomal protein 250 2.3
1453497_a_at Piga Phosphatidylinositol glycan, class A 2.3
1416693_at Foxc2 Forkhead box C2 2.2
1450781_at Hmga2 High mobility group AT-hook 2 2.2
1438527_at Rpl3 Ribosomal protein L3 2.2
1448171_at Siah2 Seven in absentia 2 2.2
1424607_a_at BC003993 K0208G08-3 NIA Mouse clone 2.2
1420380_at Ccl2 Chemokine (C-C motif) ligand 2 2.2
1417395_at Klf4 Kruppel-like factor 4 2.2
1431030_a_at Rnf14 Ring finger protein 14 2.2
1448183_a_at Hif1a Hypoxia inducible factor 1, alpha subunit 2.1
1419157_at Sox4 SRY-box containing gene 4 2.1
1418158_at Trp63 Transformation related protein 63 2.1
1421000_at Cnot4 CCR4-NOT transcription complex, subunit 4 2.1
1452161_at Tiparp TCDD-inducible poly(ADP-ribose) polymerase 2.0
1425279_at Pdik1l PDLIM1 interacting kinase 1 like 2.0
1453840_at Pabpc1 Poly A binding protein, cytoplasmic 1 2.0
1416123_at Ccnd2 Cyclin D2 2.0
1417924_at Pak3 P21-activated kinase 3 2.0
The temporal pattern of genes up-regulated in mouse myoblasts following IGF-1 treatment is tabulated based on their Venn distribution. Shown are 
genes up-regulated at: 1 hr only; 1 & 2 hrs; at 1 & 4 hrs; 1, 2 & 4 hrs and 2 hrs only (Please see Additional file 1 for genes up-regulated at 2 & 4 hrs 
and 4 hrs only).
Table 1: The temporal pattern of genes up-regulated with IGF-1 treatment (Continued)BMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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a potent inhibitor of protein synthesis. The expression of
other genes involved in the post-transcriptional regula-
tion of SREBPs, such as SREBP Cleavage Activator Protein
(Scap) (Fig. 3C and 4L) and, Site 1 protease (S1p) were not
induced, with the exception of Insig2 which again was
moderately (1.6-fold) stimulated by IGF-1 (Fig. 3C)(No
chip data was available for the Site 2 protease (S2p)). Fur-
thermore, none of the other known transcription factors/
cofactors implicated in fatty acid and cholesterol biosyn-
thesis, namely Ap1, AP2, Sp1, Sp3, Lxr, C/EBPbeta, NF-Y,
and Red25 were induced by IGF-1 treatment in this study.
Microarray data was validated using q-PCR on a selection
of 6 cholesterol biosynthetic pathway genes, namely
HMG CoA synthase 1 (Hmgcs1), HMG CoA reductase
(Hmgcr), (Mevalonate kinase (Mk), Cytochrome P450 51
(Cyp51), Lanosterol synthetase (Lss), 7 Dehydrocholestrol
reductase (7Dhcr) (Fig. 4A–F, respectively). A comparison
of the microarray and q-PCR data for each of these genes
shows that the profiles are similar. However, the extent of
induction seen with q-PCR is more profound. For
instance, microarray data for HMG CoA synthase and
HMG CoA reductase (see Fig. 2C) indicates a 3-fold
change whereas q-PCR values show a 4- to 5-fold induc-
tion at 4 hours (Figs. 4A, B). Likewise the relative expres-
sion values obtained with the other cholesterol
biosynthetic pathway genes is greater though the profiles
are quite similar. This similarity is further exemplified
Table 2: The temporal pattern of genes down-regulated with IGF-1 treatment
Affy. Id. Symbol Genes down-regulated at 1 hr only Fold Change
1420019_at Tspan8 Tetraspanin 8 0.41
1438317_a_at Endog Endonuclease G 0.44
1427298_at Dnm3os Dynamin 3, opposite strand 0.46
1456078_x_at Tubb2c Tubulin, beta 2c 0.46
1427543_s_at Ube1y1 Ubiquitin-activating enzyme E1, Chr X 0.47
1438403_s_at Ramp2 Receptor (calcitonin) activity modifying protein 2 0.48
Genes down-regulated at 1 & 2 hrs
1415996_at Txnip Thioredoxin interacting protein 0.47
Genes down-regulated at 1 & 4 hrs
1442744_at Rbm39 RNA binding motif protein 39 0.45
Genes down-regulated at 1, 2 & 4 hrs
1448830_at Dusp1 Dual specificity phosphatase 1 0.35
1416630_at Ib3 Inhibitor of DNA binding 3 0.49
Genes (23) down-regulated at 2 hrs only
1422474_at Pde4b Phosphodiesterase 4B, cAMP specific 0.29
1435872_at Pim1 Proviral integration site 1 0.32
1416488_at Ccng2 Cyclin G2 0.35
1422473_at Pde4b Phosphodiesterase 4B, cAMP specific 0.36
1427005_at Plk2 Polo-like kinase 2 0.37
1456569_x_at Gsn Gelsolin 0.39
1433668_at Pnrc1 Proline-rich nuclear receptor coactivator 1 0.41
1419080_at Gdnf Glial cell line derived neurotrophic factor 0.42
1416286_at Rgs4 Regulator of G-protein signaling 4 0.44
1460009_at Ier5 Immediate early response 5 0.45
1422195_s_at Tbx15 T-box 15 0.46
1448364_at Ccng2 Cyclin G2 0.47
1416619_at Rik RIKEN 4632428N05 gene 0.47
1450741_at Stau1 Staufen (RNA binding protein) homolog 1 0.47
1427479_at BB287469 Eukaryotic translation initiation factor1A, predicted 0.48
1434940_x_at Rgs19 Regulator of G-protein signaling 19 0.48
1437101_at Lats2 LATS2B, alternatively spliced 0.49
1452604_at Stard13 Serologically defined colon cancer antigen 13 0.49
1456528_x_at Ncl Nucleolin 0.49
1439441_x_at Lats1 Large tumor suppressor 2 0.49
1427130_x_at Rik RIKEN 1700021K02 gene 0.49
1451731_at Abc1 ATP-binding cassette, sub-family A, member 3 0.49
1453355_at Wnk2 WNK lysine deficient protein kinase 2 0.50
The temporal pattern of genes down-regulated in mouse myoblasts following IGF-1 treatment is tabulated based on their Venn distribution. Shown 
are genes down-regulated at: 1 hr only; 1 & 2 hrs; at 1 & 4 hrs; 1, 2 & 4 hrs and 2 hrs only (Please see Additional file 2 for genes down-regulated at 
2 & 4 hrs and 4 hrs only).BMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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when a comparison of data from the two analytical meth-
ods is made for Mk, Lss and Cyp51 genes. The Mk (Mvk1)
gene is markedly induced at 4 hours with both methods
but remains largely uninduced at the earlier time points
(see Figs. 2D and 4I). However, induction levels obtained
by q-PCR for the Mvk1 gene at 4 hours (Fig. 4C) are about
2-fold greater than that obtained with microarray studies.
Further, microarray data for both LSS and Cyp51 genes
show a more or less linear induction with IGF-1 that is ini-
tiated at 1 hour (Fig. 2E) and is unlike the profile obtained
for the Mvk1 gene. Again our qPCR data shows a similar
pattern of induction for both genes though the change is
about 2-fold greater at 4 hours (Figs. 4D and 4E).
The fold change profiles for 2 representative genes of the
fatty acid biosynthesis pathway, namely Fatty Acid syn-
thase (Fas) and stearoyl-Coenzyme A desaturase 1 (Scd1)
(Figs. 4G and 4H, respectively) are similar with both
methods. The Scd1 gene, and not Fas, shows a greater level
of stimulation with the q-PCR assay. Three regulatory
genes involved in fatty acid and cholesterol biosynthesis,
namely SREBP-1 & -2, and Sterol Cleavage Activator Pro-
tein (Scap) were examined (Figs. 4J, K, L respectively). The
pattern obtained is in general agreement with the Affyme-
trix GeneChip data for these genes, with the exception of
SREBP-1 where no change was detected with the microar-
ray study (Fig. 3A) as against a measurable change
detected with the q-PCR assay (Fig. 4J).
The beta-Actin gene included as an independent control
here (Fig. 4I) showed no change with IGF-1 treatment.
Further, we selected five genes unrelated to the fatty acid
or cholesterol biosynthetic pathways, namely Chac1,
Klf10, Ier2, Socs3 and Shh (Fig 4M, N, O, P and 4Q,
respectively) that show distinctive patterns of early induc-
tion based on our microarray data. In addition, we
selected Dusp1, a dual-specificity phosphatase gene (Fig.
4R), which is one of the two genes that are consistently
down-regulated over the IGF-1 treatment regime, to reflect
a gene that was repressed by IGF-1 treatment. The q-PCR
profiles for all these six genes are shown (Fig. 4M to 4R.)
and closely resemble the characteristic expression patterns
observed for each of these genes from our microarray
studies with the exception that Shh shows a slightly
delayed induction. Overall, the extent of change obtained
with q-PCR was invariably greater than that noticed with
the microarray studies.
Discussion
Global changes in gene expression
Insulin characteristically influences the up- and down-
regulation of more than 150 genes in various tissues and
induces lipogenesis in muscle cells [16]. Several target
genes induced by insulin are not affected by IGF-1 treat-
ment at any time point in this study. For instance, Glut2
(glucose transport); Glucokinase, aldolase A, phos-
phoglycerate kinase and GAPDH (glycolysis); Glucose-6
phosphate dehydrogenase (pentose phosphate); leptin
and Apolipoprotein A1 (lipid transport); calmodulin
(Calcium signaling) and Plasminogen activator inhibitor-
1 (Pai1) (fibrinolysis) genes [16] that are characteristically
up-regulated by insulin are not altered by IGF-1 treat-
ment. In contrast, we have identified a subset of genes typ-
ically activated by insulin, namely VEGF, Glut1, IGF-1,
IGFBP-3, fatty acid synthesis genes, ATP-citrate lyase, Fatty
acid synthase, Stearoyl CoA desaturase 1, cholesterol syn-
thesis and uptake genes, HMG CoA reductase, LDL recep-
tor and Egr-1  transcription factor gene, that are also
activated by IGF-1 in this study. Moreover two genes,
GAPDH and Pai1 [16] that are induced by insulin were
markedly down-regulated (2.6- and 1.8-fold, respectively)
by IGF-1 in our study.
Conversely, several liver-specific genes, known to be
down-regulated by insulin including Phospho-enolpyru-
vate carboxykinase (PEPCK), the rate limiting enzyme in
gluconeogenesis; 3-Hydroxyl-3-methylglutaryl-CoA syn-
thase-2 (Hmgcs2) involved in ketogenesis; IGFBP-1 carrier
protein; Pyruvate dehydrogenase kinase-4 (Pdk4)
involved in inhibition of lipogenesis, and two cyto-
Table 3: Fatty Acid biosynthetic pathway genes up-regulated with IGF-1 treatment
Affy. Id. Symbol Genes up-regulated at 4 hrs Fold Change
1425326_at Acyl ATP citrate lyase * 2.7
1418911_s_at Acas1 Acyl CoA synthetase * 1.9
1427595_at Acat1 Acetyl-CoA carboxylase N/C
1423828_at Fas Fatty acid synthase 2.3
1451457_at Sc5dl Delta-5 desaturase 2.0
1415824_at Scd1 Steroyl CoA desaturase 1.8
1417404_at Evol6 Elongation of Long chain FA-6 2.3
The genes involved in fatty acid biosynthesis that are induced by about two-fold or greater levels at 4 hours are listed. Only a selective number of 
fatty acid genes are induced by IGF-1. Acetyl-CoA carboxylase a key and rate-limiting enzyme in the pathway shows no detectable transcriptionally 
induction. Genes common to the fatty acid and cholesterol biosynthetic pathways (see Table 4) are indicated (*) and genes showing 'No Change' in 
expression levels are also listed (N/C).BMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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Expression profiles of fatty acid and cholesterol biosynthetic pathway genes following exposure of murine myoblasts to IGF-1 Figure 2
Expression profiles of fatty acid and cholesterol biosynthetic pathway genes following exposure of murine 
myoblasts to IGF-1. The expression values (derived from microarray studies) are plotted as relative change over untreated 
control (100) values for Fatty acid synthase (Fas), ATP citrate lyase (Acly), Acyl CoA synthetase (Acs) (Fig. 2 A; Fatty acid 
desaturase (Fads), sterol C5 desaturase (SC5d), and Stearoyl CoA desaturase 1 (Scd1) (Fig. 2B). Data shows a two-fold or 
greater induction with IGF-1 treatment for all these genes (Fig. 2 A-B). Relative gene expression profiles are also shown for the 
genes involved in cholesterol biosynthesis (Fig 2C–F), namely HMG CoA synthase 1 (Hmgcs1) and HMG CoA reductase 
(Hmgcr) (Fig. 2C); Mevalonate (diphospho) decarboxylase (Mvd), Mevalonate kinase (Mk) and Phosphomevalonate kinase 
(Pmk) (Fig. 2D). Profiles are also shown for Cyp51, Hydroxysteroid dehydrogenase 17 beta (Hsd17b7), Lanosterol synthase 
(Lss) (Fig. 2E) and for the Low density Lipoprotein receptor (Ldlr), START domain 4 (Startd4) and cholesterol 25-hydroxylase 
(M25oh) genes (Fig. 2F). The genes involved in fatty acid and cholesterol biosynthesis are coordinately induced by IGF-1, 
though subtle variations exist in the time and extent of induction. In general, the induction is about 3–4 fold.
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chromes P450, Cyp7 and Cyp8B1, are all unaffected by
IGF-1 treatment. In contrast to the down-regulation of 5-
aminolevulinate synthase-1 (ALAS1), the key and rate-
limiting enzyme in heme biosynthesis by insulin, IGF-1
induces its expression (1.9-fold). Despite the structural
similarities between the insulin and IGF-1 ligands and
their receptors, the downstream pathways affected by
these two hormones in myoblasts are different in impor-
tant respects and follow divergent action streams. The
divergent effects of insulin and IGF-1 were reported earlier
in a microarray study on mouse NIH-3T3 fibroblasts
where intracellular signals for these two peptide hor-
mones are different [12].
Alternative measures such as quantitative PCR are widely
used to validate gene expression data obtained with
microarrays. We used q-PCR methods to assay selective
genes involved in the fatty acid and cholesterol biosyn-
thetic pathways as well as genes not directly related to
these two pathways that were either induced or repressed
(Fig. 4) and found the results to be in general agreement
with the Affymetrix microarray chip data in that the direc-
tion and pattern of change were closely similar for most
genes, though the fold change seen with q-PCR was gen-
erally greater. These findings are also in agreement with
earlier reports that q-PCR validations are directional con-
firmation only and large discrepancies in the amount of
change are observed [17].
One of the early responses to IGF-1 treatment was that the
genes for a significant number of transcription factors
were markedly induced. As indicated earlier several of
these factors such as Early growth response-1 & -2, Zinc
finger protein-36, -97-like, -119 (Zfp36, Zfp97l, Zfp119),
and Immediate early response-2 genes (See Table 1), were
transiently expressed. The expression of other transcrip-
tion factors such as Snail homolog 1 (Snai1), Seven in
absentia 2 (Siah2), Kruppel-like factor 10 (Klf10), Basic
helix-loop-helix domain containing factor (Bhlhb2) is sus-
tained for the period of treatment. A large number of
Table 4: Cholesterol biosynthetic pathway genes up-regulated with IGF-1 treatment
Affy. Id. Symbol Genes up-regulated at 4 hrs Fold Change
1425326_at Acly ATP Citrate Lyase * 2.7
1422478_a_at Acas1 Acetyl CoA Synthetase * 3.3
1451271_a_at Acat Acetyl CoA Acetyltransferase N/C
1423797_at Acas Acetyl CoA Acety Synthetase 3.1
1433443_at Hmgcs1 HMG CoA Synthase 1 3.1
1427229_at Hmgcr HMGCoA Reductase 3.1
1430619_a_at Mvk Mevalonate Kinase 3.9
1427893_a_at Pmek Phosphomevalonate Kinase 3.0
1417303_at Mvd Mevalonate (diphospho) Decarboxylase 4.5
1451122_at Idi1 Isopentenyl diphosphate delta isomerase 2.9
1423418_at Fdps Farnesyl diphosphate Synthetase 1.8
1415993_at Sqe Squalene epoxidase 2.1
1426913_at Lss Lanosterol Synthase 4.6
1422533_at Cyp51 Lanosterol 14a demethylase (CYP51) 3.5
1423078_a_at Sc4mo Sterol C4 Methyl Oxidase 3.5
1416222_at Nsdhl NAD(P)H Steroid Dehydrogenase-like 2.4
1417871_at Hsd17b7 17b Hydroxysteroid Dehydrogenase 7 6.1
1424709_at Sc5d Sterol C5 Desaturase 3.0
1448619_at 7Dhcr 7 dehydrocholesterol Reductase 3.2
Uptake, breakdown & transport genes
1421821_at Ldlr LDL Receptor (Uptake) 2.0
1449227_at M25oh Cholesterol 25 hydroxylase (breakdown) 4.0
1429240_at Startd4 Star-related Lipid transfer domain containing 4 (Transport) 2.8
Regulatory genes
1426690_a_at Srebp1a Sterol Regulatory Element Binding Protein-1 1.1
1426744_at Srebp2 Sterol Regulatory Element Binding Protein-2 1.4
1433520_at Scap SREBP Cleaveage Activator Protein N/C
1448240_at S1p Site 1 protease N/C
1417980_a_at Insig2 Insulin Signal 2 (insulin induced) 1.7
The genes involved in cholesterol biosynthesis that are induced by about two-fold or greater levels at 4 hours are listed. All genes involved in 
cholesterol biosynthesis as well as those involved in cholesterol uptake (LDL receptor), break down (cholesterol 25 hydroxylase (M25oh)) and 
transport (Star-related Lipid transfer domain containing 4(Startd4)), are also up-regulated with IGF-1 treatment. Of the genes involved in the 
regulation of cholesterol biosynthesis only Srebp2 and Insig2 are feebly up-regulated, whereas Scap and S1p genes are unaffected. There is no 
available chip data on S2p. Genes common to the fatty acid and cholesterol biosynthetic pathways are indicated (*) and genes showing 'No Change' 
in expression levels are also listed (N/C).BMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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genes are either up- or down-regulated and belong to a
mixed array of gene ontologies. However, it was interest-
ing that some genes belonging to the fatty acid biosyn-
thetic pathway and most genes of the cholesterol
biosynthetic pathway were coordinately up-regulated at 4
hours following exposure of murine C2C12 myoblasts to
IGF-1(Tables 3 and 4).
Only a few of the 30 genes reported by Dupont and cow-
orkers [11] from their 90 min study on IGF-1 treated
NIH3T3 cells are up-regulated in our study on C2C12
myoblasts; namely, the Early growth response 1 and a
Splicing factor, arginine/serine 3, gene. C2 cells treated for
24 hours with an IGF-1 analogue R3-IGF-1 were shown to
up-regulate about 90 genes, of which 28 were muscle-spe-
cific [13]. The large number of muscle-specific genes
induced by this prolonged exposure to IGF-1 (or its ana-
logue) is consistent with its role in myoblast differentia-
tion. The lack of a similarity between the above two
reports and the present study with mouse C2C12 myob-
Genes involved in the regulation of fatty acid and cholesterol biosynthetic pathways Figure 3
Genes involved in the regulation of fatty acid and cholesterol biosynthetic pathways. Microarray data show no sig-
nificant change in SREBP-1 and -2 gene expression with IGF-1 treatment (Fig. 3A). However, when cycloheximide was added in 
conjunction with IGF-1 (IGF-1+CHX) to block nascent protein synthesis, both genes were activated to low and comparable 
extents, suggesting a similar pattern of regulation via 'derepression' (Fig. 3B). This level of 'derepression' was not seen with 
CHX treatment alone (data not shown). Insig2, Scap, S1p and S2p, are genes associated with SREBP-mediated lipogenesis, of 
these only Insig2 expression is moderately (1.6-fold) up-regulated (Fig 3C).
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Qantitative-PCR based assay for selective fatty acid, cholesterol biosynthetic pathway and regulatory genes following IGF-1  treatment Figure 4
Qantitative-PCR based assay for selective fatty acid, cholesterol biosynthetic pathway and regulatory genes 
following IGF-1 treatment. The relative abundance of mRNA as compared to untreated control samples was assayed by q-
PCR and plotted on a histogram for 6 genes involved in the cholesterol biosynthetic pathway, namely for HMG CoA synthase 
1 (Hmgcs1), HMG CoA reductase (Hmgcr), (Mevalonate kinase (Mk/Mvk1), Cytochrome P450 51 (Cyp51), Lanosterol syn-
thetase (Lss), and Dehydrocholestrol reductase (7Dhcr) (Fig. 4 A–F); 2 genes involved in fatty acid biosynthesis, namely Fatty 
Acid synthase (Fas) and stearoyl-Coenzyme A desaturase 1 (Scd1)(Fig. 4G and 4H); and 3 regulatory genes involved in fatty 
acid and cholesterol biosynthesis, namely SREBP-1 and -2, and Sterol Cleavage Activator Protein (SCAP) (Fig. 4J, 4K and 4L). 
The beta-Actin mRNA was assayed here as a control (Fig. 4I). In addition, 6 other genes unrelated to the fatty acid or choles-
terol pathways were assayed; namely Chac1, Klf10, Ier2, Socs3, Shh and Dusp1 (Fig. 4 M-R, respectively) and the data show 
that the expression profile for all of these genes is similar to patterns obtained from our microarray experiments. The pattern 
obtained is in general agreement with the Affymetrix GeneChip data for these genes, with the exception of SREBP-1 where no 
change was detected with the microarray study. The extent of induction obtained with q-PCR, however, is greater than the 
microarray hybridization signals, probably due to the greater dynamic range observed with PCR amplification.
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lasts is likely due to the differences in cell types, induction
times and IGF-1 employed in the respective studies, and
therefore it is not surprising that there are few common
patterns.
Regulation of Fatty Acid and Cholesterol genes
Insulin has been implicated in triggering lipogenesis and
most evidence suggests that this stimulation is brought
about via the induction of the SREBPs and other partner
proteins associated with their transcription as well as post-
transcriptional regulation. There is no transcriptional evi-
dence to suggest that this coordinate up-regulation of
lipogenesis in myoblasts, normally considered an insulin
response, is modulated by the hierarchical SREBPs. For
instance the SREBP-1 transcription factor, implicated in
the induction of fatty acid biosynthesis [14], was not tran-
scriptionally activated by IGF-1 in our microarray study
(Figs. 3A). Although, SREBP-1 is reported to self-induce its
own transcription by a 'feed-forward loop' mechanism
[18] we failed to see any significant transcriptional
enhancement in myoblasts. Further, SREBP-2 is modestly
(1.4-fold) affected by IGF-1 in our microarray (Fig. 3A)
(and q-PCR, Fig. 4K) study. The related SREBP cleavage
activating protein (SCAP) (Fig. 3C and Fig. 4L) and the
membrane bound Site 1 and 2 peptidases (S1p and S2p)
are not transcriptionally induced. However, INSIG2,
which triggers SREBP cleavage, is moderately (1.6-fold)
induced (Fig. 3C). It should be pointed out that SREBP-1a
and -1c mRNAs differ only in their 5' coding regions
(SREBP-1a mRNA encodes 28 additional N-terminal
amino acids whereas SREBP-1c lacks this region but has 4
unique amino acids. The mRNA sequences downstream
from this region are identical in both isoforms). The
Affymetrix mouse chip and our q-PCR analysis target the
common 3' region of SREBP-1a and SREBP-1c and hence
relate to both isoforms (-1a & -1c). However, it is reported
that SREBP-1a is a potent activator of gene expression as
compared to the relatively weak inducer activity associ-
ated with SREBP-1c [19].
Several transcription factors are implicated in insulin-
mediated regulation of fatty acids and cholesterol biosyn-
thesis, including AP1, AP2, SREBP-1a, -1c and -2, Sp1,
Sp3, LXR, C/EBPbeta, NF-Y, and Red25 [16]. None of the
aforementioned factors record a change in their relative
gene expression signal levels with 4 hours of IGF-1 treat-
ment. An alternative explanation is that the post-tran-
scriptional regulation of SREBPs, as outlined in several
earlier studies [14], could account for the coordinate
induction of fatty acid and cholesterol biosynthetic genes
following IGF-1 treatment.
Tjian and coworkers [20] have reported that the CREB-
binding protein (CBP) and p300 (a CBP-related protein,
CrP) are transcriptional coactivators that interact with
SREBP promoters. Coexpression with p300 dramatically
increases the expression of both SREBP-1a and -2 [21].
Our data indicate that neither of the co-activators, CBP or
p300 is up-regulated. It is reported that cholesterol bio-
synthesis depends almost entirely on SREBPs whereas
fatty acid synthesis is only partially dependent on these
factors [18]. However, the lack of induction of these coac-
tivators (CBP or p300) with IGF-1 treatment may account
for the poor transcriptional induction of SREBPs and fur-
ther support the proposal that post-transcriptional path-
ways operate to induce fatty acid and cholesterol
biosynthesis in myoblasts.
SREBPs are the master regulators of lipid homeostasis and
SREBP-1 and SREBP-2 are known to preferentially up-reg-
ulate genes involved in fatty acid or cholesterol biosynthe-
sis, respectively [22]. Brown and coworkers (see [15]) in a
series of interesting experiments in CHO cells involving
IGF-1, used a PI3K inhibitor to inactivate Akt or expressed
a dominant-negative form of Akt and have reported that
IGF-1 induced fatty acid and cholesterol biosynthesis by a
process mediated via the PI3K/Akt pathway. More inter-
estingly, IGF-1 induces the transport of SCAP, the SREBP
cleavage-activating protein that escorts SREBP from the
endoplasmic reticulum to the Golgi by a process which
can be blocked with LY294002, which inhibits PI3K and
can, thereby, affect Akt activity. The cleavage of SREPBs to
release the active transcriptional factor operates through
the stimulation of the PI3K/Akt pathway by IGF-1, which
in turn induces the transport of SCAP and SREBP to the
Golgi and eventually results in the processing of SREBP.
Processed SREBPs are localized to the nucleus to ulti-
mately trans-activate fatty acid and cholesterol genes. It is
therefore plausible that the IGF-1-mediated induction of
fatty acid and cholesterol biosynthesis pathways elabo-
rately delineated by Brown and coworkers [15] is likely to
operate by a wholly post-transcriptional process and
occurs as an early stimulatory event in IGF-1 treated
myoblasts that are devoid of any significant transcrip-
tional expression of SREBPs. It is also possible that other
post-transcriptional mechanisms operate similar to the
insulin-dependent phosphorylation of SREBP-1c that was
recently shown to promote its transcriptional activity
[23].
Conclusion
In summary, the present studies suggest that the acute
action of IGF-1 in murine myoblast, besides inducing and
repressing an array of genes of diverse ontologies as pre-
sented here, also brings about the coordinate induction of
several fatty acid and cholesterol biosynthetic pathway
genes, probably through the trans-activation of the hierar-
chical SREBP transcription factors through a previously
elucidated subtle post-transcriptional mechanism that
occurs via Akt, initiating the transport of SCAP to theBMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
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Golgi and leads to increased proteolytic activation of
SREBPs. Another important avenue to explore is whether
other factors cooperatively influence lipogenesis in myob-
lasts together with the SREBPs, following induction by
IGF-1.
Methods
The following reagents were commercially obtained:
Mouse skeletal myoblast cell line, C2C12 (ATCC, CRL
1772); Delbeco's Modified Eagle Media (DMEM), fetal
calf serum (FCS) and PBS from Gibco; recombinant
human IGF-1 from Chemicon (Temecula, CA); cyclohex-
imide (CHX) from Calbiochem (San Diego, CA); oligonu-
cleotide pairs for q-PCR were chemically synthesized by
ValueGene (San Diego, CA); SuperScript First Strand Syn-
thesis System from InVitrogen (Carlsbad, CA, USA);
Quantitech Syber Green PCR kit from Qiagen (Valencia,
CA). RNA was isolated using the RNAeasy and QIAshred-
der kits from Qiagen and prepared for hybridization using
the Message Amp II aRNA kit from Ambion (Austin, Tx);
bio-11-CTP and Bio-16-UTP were purchased from Enzo
Life Sciences (Farmingdale, NY). The GeneChip Mouse
Expression Array 430A from Affymetrix (Santa Clara, CA)
was used in these studies. All other reagents were of
molecular biology grade.
Cell culture
Mouse C2C12 myoblasts were grown to confluency in
100 mm plates and maintained in DMEM containing
10% FCS. Prior (10 min) to treatment, media were aspi-
rated from culture dishes and cells were washed twice with
1× PBS to remove residual serum. Cells were incubated in
serum-deprived DMEM media (2 ml) at 37°C with 5%
C02 for 1, 2 and 4 hours, to which one of the following
conditions was added: a) 1× PBS; b) IGF-1; c) IGF-1+CHX
or d) CHX alone. A zero time point sample was also
included. The final concentrations of recombinant IGF-1
and cycloheximide were 100 ng/ml and 100 μg/ml,
respectively. The dose of IGF-1 selected was close to phys-
iological concentration (range 75–125 ng/ml). Each set of
treatment conditions was prepared in batches prior to
addition to triplicate culture plates and the entire experi-
mental set was independently repeated. Samples of cul-
ture media were screened prior to RNA isolation for
mycoplasma (UCSD Microplasma Core Facility) and were
found to be free from contamination.
Isolation and labeling of RNA
At each time point, batches of cell culture plates were
washed in cold PBS (1×), aspirated and rapidly frozen
with liquid nitrogen and stored at -80°C. Cells were har-
vested by scraping with a rubber policeman and total RNA
was extracted using the Qiagen RNeasy kit according to
manufacturer's instructions. The quality and quantity of
total RNA samples pooled (from triplicate plates) were
examined using an Agilent 2100 Bioanalyzer. Single and
double stranded cDNA were prepared from the total RNA
using Ambion's Message Amp II kit. Briefly, 4 μg of mRNA
was used to generate first-strand cDNA by using a T7-
linked oligo(dT) primer. After second-strand synthesis, T7
polymerase directed in vitro transcription was performed
in the presence of biotin-labeled UTP and CTP (Enzo Life
Sciences) to generate biotin-incorporated cRNA using
Ambion's Message Amp II cRNA amplification system. A
complete description of these procedures are available at
the Ambion website http://www.ambion.com/techlib/
prot/fm_1751.pdf. The quality and purity of duplicate
cRNA samples were again assessed with the Agilent 2100
Bioanalyzer. The cRNA (samples pooled from triplicate
plates each derived from a duplicate set of experiments)
were used in a duplicate set of arrays.
The UCSD GeneChip Core Facility performed dye labe-
ling, fragmentation, hybridization, washing and subse-
quent scanning of the arrays according to the procedures
recommended by the manufacturer http://www.affyme
trix.com. All experiments were performed using the
Affymetrix Mouse Expression 430A oligonucleotide
arrays, using protocols as described on the manufacturer's
website http://www.affymetrix.com/products/arrays/. The
Affymetrix Mouse 430A chip contains primarily probe sets
against well annotated full-length genes. The target cRNA
generated was processed as per the recommendations of
the manufacturer http://www.affymetrix.com/support/
technical/manual/expression_manual.affx. Controls were
spiked to 10 μg of fragmented cRNA samples and these
were hybridized overnight using the Affymetrix Hybridi-
zation Oven 640. Arrays were then washed and stained
with streptavidin-phycoerythrin using the Affymetrix
GeneChip Fluidics Station 450 and finally scanned using
an Affymetrix GeneChip® Scanner 3000-7G. A complete
description of these procedures is available at http://
www.affymetrix.com. After scanning, array images were
assessed to confirm scanner alignment and the absence of
significant bubbles or scratches on the chip surface. The
3'/5' ratios for GAPDH and beta-actin were confirmed to
be within acceptable limits (< 3.0). The BioB spike con-
trols were found to be present on all chips and, the BioC,
BioD and CreX controls were present in increasing inten-
sities. Scaling factors for all arrays were within acceptable
limits as were background, Q values and mean intensities.
Data Analysis
Scanned array images were converted to intensity values
for each probe and chip using the Affymetrix MAS 5.0 soft-
ware and arrays that met the acceptable Affymetrix criteria
were used for further analysis. All microarray data were
scaled to a standard target intensity of 500 using Affyme-
trix's MAS 5.0 software. The raw data were transferred to
the GeneSpring (Agilent Technologies/Silicon Genetics)BMC Genomics 2008, 9:535 http://www.biomedcentral.com/1471-2164/9/535
Page 14 of 15
(page number not for citation purposes)
or VAMPIRE (variance-modeled posterior inference with
regional exponentials) microarray suite [24] for data anal-
yses. The one-color (Affymetrix) data from duplicate
hybridization experiments were normalized on a per-chip
and per-gene basis using the GeneSpring protocol, filtered
for 'Present (P) only' genes, then for fold-change (2-fold
or greater) over zero time point values and finally the rel-
ative expression levels plotted for the different time points
for selected genes. Differentially expressed genes reported
here, using the GeneSpring Computer Software, are based
on average signal intensities indicating up- (i.e. 2-fold or
greater) or down-regulation (0.5 or less) following IGF-1
treatment, as compared to untreated samples at the differ-
ent time points. Raw data below a signal threshold (of
100) were generally filtered out as background noise
unless the profiles indicated reproducible and markedly
higher signal levels at some other time point of treatment.
All expression data are based on averaged normalized rel-
ative fold change or averaged raw signal intensity values.
Data presented here conforms to the proposed MIAME
criteria [25] and checklist http://www.mged.org/Work
groups/MIAME/miame.html. Comparisons using the
Vampire Software and the accompanying Goby gene
ontology database, are based on differential expression of
duplicate set of genes between treated and control sam-
ples, that are statistically significant (p = < 0.05). The fold
change (2-fold or greater) values presented here are cor-
rected to one and two decimal places for the up- and
down-regulated genes, respectively.
Quantitative-PCR
Validation of microarray expression data was carried out
using quantitative PCR for selective genes (see Fig. 4). For
this study, cDNA was generated from the pooled replicate
samples of total RNA using SuperScript First Strand Syn-
thesis enzyme (InVitrogen) for the initial reverse tran-
scription reaction. Custom-synthesized (Valuegene, San
Diego, CA) gene-specific oligonucleotide pairs were used.
Four replicate q-PCR reactions were set up for each time
point, comprising cDNA samples, SyberGreen Master Mix
(Qiagen), RNAse-free water and the appropriate primer
pair in a final volume of 20 ml. Suitable volumes of
pooled mixes were prepared and aliquots were used in the
replicate tubes to minimize experimental error. Reactions
were carried out in a MJ Research Instrument (Opticon 2,
Bio-Rad, Carlsbad, CA) and included the following steps;
denaturation for 15 seconds at 94°C; annealing for 30
seconds at 55°C; extension for 30 seconds at 72°C for 35
cycles.
Abbreviations
CHX: cycloheximide; IGF-1: insulin-like growth factor 1;
IR: insulin receptor; IGF1R: IGF-1 receptor; INSIG1: insu-
lin stimulated gene 1; SRE: sterol regulatory element;
SREBP: SRE binding protein; SCAP: sterol cleavage activa-
tor protein; S1p & S2p: Site 1 & 2 protease, respectively.
Abbreviation for genes (gene symbols) are tabulated
alongside the full names in the appropriate tables.
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